Medicare Enrolled
Dr. Joseph Lamantia, D.O.
Family Medicine · Indiana, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lamantia from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lamantia?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lamantia
Dr. Joseph Lamantia is a family medicine specialist in Indiana, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lamantia performed 1,232 Medicare services across 611 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lamantia received a total of $23,795 from 56 pharmaceutical and/or device companies across 1530 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lamantia is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 19% volume in PA
$23,795 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,232
Medicare services
Top 19% in PA for family medicine
611
Unique beneficiaries
$49
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~62 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
271 | $55 | $100 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
192 | $0 | $1 |
| Annual depression screening | 95 | $17 | $25 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
93 | $123 | $175 |
| Home visit, established patient, low complexity A physician visits an existing patient at their residence to provide care involving a low level of medical decision making. The visit lasts at least 30 minutes. |
90 | $56 | $115 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
68 | $60 | $100 |
| Home visit, established patient, moderate complexity A home visit for an established patient involving moderate medical decision making. The visit requires at least 40 minutes of time if time is used to determine the level of service. |
55 | $92 | $160 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
54 | $7 | $35 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
51 | $29 | $35 |
| Quadrivalent influenza vaccine, preservative-free A flu shot containing four strains of the influenza virus, formulated without preservatives, administered in a 0.5 ml dose. |
50 | $22 | $30 |
| Ketorolac injection, per 15 mg An injection of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug, administered in doses measured per 15 mg. |
50 | $0 | $2 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
47 | $75 | $150 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
28 | $91 | $125 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
25 | $126 | $220 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
21 | $196 | $275 |
| Hospital discharge day management, 30 minutes or less This service covers the final day of hospital care when the patient is being discharged. It includes coordination of care and instructions for the patient within a time frame of 30 minutes or less. |
20 | $59 | $100 |
| COVID-19 vaccine administration Administration of a single dose of the coronavirus vaccine. |
11 | $39 | $40 |
| COVID-19 vaccine (Moderna bivalent) An intramuscular injection of the SARS-CoV-2 vaccine containing 50 micrograms in a 0.5 mL dose. |
11 | $44 | $45 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$23,795
Total received (2018-2024)
Avg $3,399/year across 7 years
Top 1% in PA for family medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
56
Companies
1,530
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$23,795 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,664
2023
$3,246
2022
$3,802
2021
$4,419
2020
$2,586
2019
$3,017
2018
$3,061
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$494
Phathom Pharmaceuticals, Inc.
$461
Amgen Inc.
$413
PFIZER INC.
$324
ABBVIE INC.
$297
Azurity Pharmaceuticals, Inc.
$206
Bayer Healthcare Pharmaceuticals Inc.
$180
Boehringer Ingelheim Pharmaceuticals, Inc.
$168
Novo Nordisk Inc
$165
Novartis Pharmaceuticals Corporation
$157
Lilly USA, LLC
$140
Exact Sciences Corporation
$98
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$75
SHIELD THERAPEUTICS INC
$72
ACADIA Pharmaceuticals Inc
$63
Janssen Pharmaceuticals, Inc
$62
Takeda Pharmaceuticals U.S.A., Inc.
$61
Esperion Therapeutics, Inc.
$53
Electromed, Inc.
$44
GlaxoSmithKline, LLC.
$35
Astellas Pharma US Inc
$26
Ultragenyx Pharmaceutical Inc.
$21
Paratek Pharmaceuticals, Inc.
$18
Otsuka America Pharmaceutical, Inc.
$15
Currax Pharmaceuticals LLC
$15
Top 3 companies account for 37.3% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$3,392
Novo Nordisk Inc
$1,984
Amgen Inc.
$1,767
GlaxoSmithKline, LLC.
$1,359
Lilly USA, LLC
$1,090
ABBVIE INC.
$1,087
PFIZER INC.
$1,086
Novartis Pharmaceuticals Corporation
$1,041
Amarin Pharma Inc.
$914
Boehringer Ingelheim Pharmaceuticals, Inc.
$872
Janssen Pharmaceuticals, Inc
$788
Allergan Inc.
$664
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$652
Kowa Pharmaceuticals America, Inc.
$636
AbbVie Inc.
$626
Merck Sharp & Dohme Corporation
$587
Takeda Pharmaceuticals U.S.A., Inc.
$577
Phathom Pharmaceuticals, Inc.
$461
Allergan, Inc.
$360
Biohaven Pharmaceutical Holding Company Ltd.
$352
Esperion Therapeutics, Inc.
$335
ARBOR PHARMACEUTICALS, INC.
$269
Bayer Healthcare Pharmaceuticals Inc.
$268
Exact Sciences Corporation
$267
Biohaven Pharmaceuticals, Inc.
$266
Azurity Pharmaceuticals, Inc.
$258
Electromed, Inc.
$252
Synergy Pharmaceuticals Inc
$150
Bayer HealthCare Pharmaceuticals Inc.
$133
Astellas Pharma US Inc
$130
SANOFI-AVENTIS U.S. LLC
$127
Daiichi Sankyo Inc.
$120
Merck Sharp & Dohme LLC
$95
Lundbeck LLC
$76
SHIELD THERAPEUTICS INC
$72
ACADIA Pharmaceuticals Inc
$63
Arbor Pharmaceuticals, Inc.
$55
Genentech USA, Inc.
$52
E.R. Squibb & Sons, L.L.C.
$49
Paratek Pharmaceuticals, Inc.
$48
Currax Pharmaceuticals LLC
$47
Alkermes, Inc.
$41
IDORSIA PHARMACEUTICALS US INC
$39
Eisai Inc.
$38
Sunovion Pharmaceuticals Inc.
$37
IRONWOOD PHARMACEUTICALS, INC
$34
Jazz Pharmaceuticals Inc.
$33
Ultragenyx Pharmaceutical Inc.
$21
Celgene Corporation
$17
SANOFI PASTEUR INC.
$17
Orexigen Therapeutics, Inc.
$16
Teva Pharmaceuticals USA, Inc.
$16
Shire North American Group Inc
$15
Otsuka America Pharmaceutical, Inc.
$15
EISAI INC.
$14
Noden Pharma USA Inc
$12
Top 3 companies account for 30.0% of all-time payments
Associated products mentioned in payments ›
ACCRUFER · AIRSUPRA · AJOVY · ANORO · ANORO ELLIPTA · Aimovig · Amitiza · BASAGLAR · BELSOMRA · BEVESPI AEROSPHERE · BEXSERO · BREO · BREZTRI · BRILINTA · BYSTOLIC · CHANTIX · COMIRNATY · CONTRAVE · CREON · Cologuard Collection Kit · Crysvita · DALVANCE · Dayvigo · EDARBI · EDARBYCLOR · ELIQUIS · EMGALITY · ENTRESTO · EUCRISA · EVENITY · Edarbi · Edarbyclor · FARXIGA · FASENRA · FLUZONE QUADRIVALENT NORTHERN HEMISPHERE · HORIZANT · Horizant · INJECTAFER · INVOKANA · JANUVIA · JARDIANCE · Kerendia · LATUDA · LEQVIO · LINZESS · LYRICA · Linzess · Livalo · MOTEGRITY · MOUNJARO · MYDAYIS · MYRBETRIQ · Motegrity · Myrbetriq · NEXLETOL · NEXLIZET · NUPLAZID · NURTEC ODT · NUZYRA · ONZETRA XSAIL · Otezla · Ozempic · PAXLOVID · PREVNAR 20 · Prolia · QULIPTA · QUVIVIQ · REXULTI · RYBELSUS · Repatha · Rybelsus · SEGLENTIS · SHINGRIX · SIVEXTRO · SMARTVEST · SOLIQUA · STEGLATRO · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · SYNJARDY · Saxenda · TEKTURNA · TEZSPIRE · TOUJEO · TRADJENTA · TRELEGY ELLIPTA · TRINTELLIX · TRULANCE · TRULICITY · Tresiba · Trintellix · Trulance · UBRELVY · Uloric · Utibron · VIBERZI · VIVITROL · VOQUEZNA · VRAYLAR · VYEPTI · VYVANSE · Vascepa · Veozah · Victoza · Wegovy · XARELTO · XIFAXAN · Xofluza
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 1% for family medicine in PA.
Geographic Context
Family medicine physicians within 10 mi
111
Per 100K population
133.4
County median income
$58,739
Nearest hospital
INDIANA REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lamantia is a clinical cardiology specialist, with above-average Medicare volume (top 19% in PA), with low-engagement industry engagement in the top 1% of PA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lamantia experienced with office visit, established patient (20-29 min)?
Based on Medicare claims data, Dr. Lamantia performed 271 office visit, established patient (20-29 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lamantia receive payments from pharmaceutical companies?
Yes. Dr. Lamantia received a total of $23,795 from 56 companies across 1,530 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lamantia's costs compare to other family medicine physicians in Indiana?
Dr. Lamantia's average Medicare payment per service is $49. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lamantia) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicine Physicians in Indiana
Browse family medicine physicians in Indiana ranked by procedure volume and transparency data.
Highest volume
Top Family Medicine Physicians in PA
Family medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicine Physicians in PA
Which PA family medicine physicians receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novo Nordisk Inc Payments to Doctors
See all physicians who received payments from Novo Nordisk Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology